Total Payments
$212,615
2024 Payments
$14,188
Companies
21
Transactions
140
Medicare Patients
288
Medicare Billing
$35,387
Payment Breakdown by Category
Consulting$105,858 (49.8%)
Travel$36,719 (17.3%)
Other$33,480 (15.7%)
Research$33,093 (15.6%)
Food & Beverage$3,415 (1.6%)
Education$50.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $105,858 | 36 | 49.8% |
| Travel and Lodging | $36,719 | 40 | 17.3% |
| Unspecified | $33,093 | 1 | 15.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $25,580 | 5 | 12.0% |
| Honoraria | $7,900 | 3 | 3.7% |
| Food and Beverage | $3,415 | 54 | 1.6% |
| Education | $50.00 | 1 | 0.0% |
Payments by Type
General
$179,522
139 transactions
Research
$33,093
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $44,181 | 51 | $0 (2024) |
| Eli Lilly and Company | $33,093 | 1 | $0 (2021) |
| GENZYME CORPORATION | $23,473 | 9 | $0 (2019) |
| Janssen Biotech, Inc. | $18,378 | 10 | $0 (2018) |
| Clovis Oncology, Inc. | $15,871 | 12 | $0 (2021) |
| Amgen Inc. | $12,544 | 8 | $0 (2018) |
| PFIZER INC. | $12,243 | 5 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $9,368 | 11 | $0 (2018) |
| Advanced Accelerator Applications | $8,679 | 4 | $0 (2021) |
| TOLMAR Pharmaceuticals, Inc. | $5,979 | 6 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14,188 | 7 | PFIZER INC. ($10,118) |
| 2023 | $1,600 | 1 | Tolmar, Inc. ($1,600) |
| 2021 | $35,730 | 4 | Eli Lilly and Company ($33,093) |
| 2020 | $28,294 | 19 | Bayer HealthCare Pharmaceuticals Inc. ($11,595) |
| 2019 | $33,757 | 32 | Bayer HealthCare Pharmaceuticals Inc. ($16,006) |
| 2018 | $52,540 | 30 | GENZYME CORPORATION ($23,043) |
| 2017 | $46,506 | 47 | Amgen Inc. ($12,394) |
All Payment Transactions
140 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $128.21 | General |
| Category: Oncology | ||||||
| 12/07/2024 | Tolmar, Inc. | — | Honoraria | Cash or cash equivalent | $1,800.00 | General |
| 11/21/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Consulting Fee | Cash or cash equivalent | $2,142.00 | General |
| Category: Oncology | ||||||
| 10/29/2024 | PFIZER INC. | XTANDI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $8,500.00 | General |
| Category: ONCOLOGY | ||||||
| 10/11/2024 | PFIZER INC. | XTANDI (Drug) | Travel and Lodging | In-kind items and services | $227.55 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2024 | PFIZER INC. | XTANDI (Drug) | Travel and Lodging | In-kind items and services | $899.76 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2024 | PFIZER INC. | XTANDI (Drug) | Travel and Lodging | In-kind items and services | $490.73 | General |
| Category: ONCOLOGY | ||||||
| 07/26/2023 | Tolmar, Inc. | ELIGARD (Drug) | Honoraria | Cash or cash equivalent | $1,600.00 | General |
| Category: Prostate Cancer | ||||||
| 11/05/2021 | Progenics Pharmaceuticals, Inc. | PYLARIFY (Drug) | Food and Beverage | In-kind items and services | $86.58 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 10/12/2021 | Clovis Oncology, Inc. | Rubraca (Drug) | Education | In-kind items and services | $50.00 | General |
| Category: Oncology | ||||||
| 08/17/2021 | Eli Lilly and Company | — | — | Cash or cash equivalent | $33,093.00 | Research |
| Study: A STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CANCER | ||||||
| 08/13/2021 | Advanced Accelerator Applications | — | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| 12/25/2020 | Janssen Research & Development, LLC | ERLEADA (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Oncology | ||||||
| 12/16/2020 | Bayer HealthCare Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| 11/07/2020 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Consulting Fee | Cash or cash equivalent | $2,175.00 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 07/29/2020 | Bayer HealthCare Pharmaceuticals Inc. | Nubeqa (Drug) | Consulting Fee | Cash or cash equivalent | $4,512.00 | General |
| Category: Oncology | ||||||
| 07/21/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| Category: Oncology | ||||||
| 06/19/2020 | Advanced Accelerator Applications | LUTATHERA (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: ONCOLOGY | ||||||
| 05/28/2020 | Clovis Oncology, Inc. | Rubraca (Drug) | Consulting Fee | Cash or cash equivalent | $4,770.00 | General |
| Category: Oncology | ||||||
| 05/28/2020 | Clovis Oncology, Inc. | Rubraca (Drug) | Food and Beverage | In-kind items and services | $27.98 | General |
| Category: Oncology | ||||||
| 04/24/2020 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 02/12/2020 | Exelixis Inc. | Cabometyx (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,980.00 | General |
| Category: Oncology | ||||||
| 02/12/2020 | Bayer HealthCare Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $65.78 | General |
| 02/12/2020 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $45.74 | General |
| Category: Oncology | ||||||
| 02/10/2020 | Bayer HealthCare Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $3,850.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CANCER | Eli Lilly and Company | $33,093 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 36 | 63 | $28,653 | $4,015 |
| 2022 | 1 | 59 | 112 | $47,556 | $7,635 |
| 2021 | 5 | 138 | 206 | $79,108 | $17,621 |
| 2020 | 2 | 55 | 111 | $31,587 | $6,116 |
Total Patients
288
Total Services
492
Medicare Billing
$35,387
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 36 | 63 | $28,653 | $4,015 | 14.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 59 | 112 | $47,556 | $7,635 | 16.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 75 | 135 | $49,617 | $10,578 | 21.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 23 | 23 | $16,059 | $3,352 | 20.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 12 | 14 | $6,878 | $1,626 | 23.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 14 | 17 | $2,258 | $1,265 | 56.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 14 | 17 | $4,296 | $800.25 | 18.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 39 | 86 | $29,762 | $5,155 | 17.3% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 16 | 25 | $1,825 | $961.17 | 52.7% |
About Dr. Charles Ryan, MD
Dr. Charles Ryan, MD is a Internal Medicine healthcare provider based in Minneapolis, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1083672000.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Charles Ryan, MD has received a total of $212,615 in payments from pharmaceutical and medical device companies, with $14,188 received in 2024. These payments were reported across 140 transactions from 21 companies. The most common payment nature is "Consulting Fee" ($105,858).
As a Medicare-enrolled provider, Ryan has provided services to 288 Medicare beneficiaries, totaling 492 services with total Medicare billing of $35,387. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Medical Oncology, Medical Oncology
- Location Minneapolis, MN
- Active Since 05/01/2006
- Last Updated 11/13/2018
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1083672000
Products in Payments
- Erleada (Drug) $23,325
- JEVTANA (Drug) $22,836
- Rubraca (Drug) $15,871
- XGEVA (Biological) $12,544
- Non-Covered (Drug) $10,225
- XTANDI (Drug) $10,118
- ELIGARD (Drug) $7,579
- Xofigo (Drug) $7,074
- Nubeqa (Drug) $6,782
- ZYTIGA (Drug) $3,027
- OPDIVO (Biological) $2,700
- PROVENGE (Drug) $2,175
- Cabometyx (Drug) $2,026
- LUTATHERA (Drug) $2,000
- ERLEADA (Drug) $1,000
- NO PRODUCT DISCUSSED (Drug) $637.30
- PYLARIFY (Drug) $86.58
- Non-Covered $20.53
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Minneapolis
Dr. Jay Cohn, M.d, M.D
Internal Medicine — Payments: $924,540
Internal Medicine $924,540
Dr. Nedaa Skeik, Md, MD
Internal Medicine — Payments: $669,804
Internal Medicine $669,804
Mark Reding, Md, MD
Internal Medicine — Payments: $607,358
Internal Medicine $607,358
Wesley Pedersen, Md, MD
Internal Medicine — Payments: $595,626
Internal Medicine $595,626
Shilpa Gupta, Md, Mbbs, MD, MBBS
Internal Medicine — Payments: $528,257
Internal Medicine $528,257
Dr. Marshall Hertz, M.d, M.D
Internal Medicine — Payments: $398,078
Internal Medicine $398,078